According to the statistics of the arterial network database, there were 249 financing events in the global medical and health industry in 2018Q1, a year-on-year decrease of 13.5%, and the financing amount exceeded US$6.5 billion, a year-on-year increase of 7.5%. Among them, the financing of biotechnology is the hottest, and the number of financing events and financing amount ranks first, with 52 financing events and financing exceeding US$2.5 billion.
The main points of the report:
The scale of financing in the medical and health industry has increased, and the growth rate has slowed down;
The field of biotechnology has the most gold, and the financing of medical support and medical tools is cold;
The A round, the seed and the angel round, and the B round are in the top three, and the financing moves in the mature direction;
Domestic biotechnology has the largest amount of financing, and the performance of primary medical and consumer medical fields is outstanding;
The financing of the domestic economically developed regions is the hottest, and the 30% financing incident occurred in Beijing;
Dinghui, Sequoia and Jingwei are the most active, and the biotechnology, medicine, science and technology medical fields are the most popular.
The scale of financing in the medical and health industry has increased, and the growth rate has slowed down.
In 2018Q1, there were 249 financing incidents in the global healthcare industry, down 13.5% year-on-year, mainly due to the significant decrease in the number of financing events in the medical device and technology medical fields. The financing amount exceeded US$6.5 billion, a year-on-year increase of 7.5%, and the growth rate slowed down.
Since 2011, the global medical and health industry's single financing has increased year by year, and 2018Q1 has reached a historical peak of US$26.16 million. This is because the industry is gradually maturing and capital is overweight.
Biotechnology and medicine are the most absorbing, and the financing of medical support and medical tools is cold.
Among the 2018Q1 medical and health industry segments, biotechnology has the largest amount of gold, and the number of financing events and financing amount rank first. Medicine, medical equipment, primary care, and medical informationization are also quite eye-catching.
It is worth noting that only 2018Q1, the number of financing activities in blockchain enterprises in medical informatization reached 12, exceeding 50% of the total number of financing activities of blockchain enterprises in 2017, and the financing amount of blockchain enterprises exceeded US$43.92 million. 10% of the total amount of financing in the quarter of medical information.
A round, seed and angel wheel, B wheel is in the top three, financing moves in the mature direction
In the global medical and health industry of 2018Q1, the financing rounds are mainly seed and angel round, A round and B round. The number of A round financing events reached 35% of the total financing items. Analysis of the financing rounds over the years shows that financing moves in the mature direction.
Large amount of financing in biotechnology
2018Q1 Global Healthcare Industry Financing TOP10
The 2018Q1 global medical and health industry financing TOP10 project financing amount exceeds 100 million US dollars, and the financing TOP10 project is distributed in the fields of biotechnology, medicine, medical equipment, primary care, and medical finance. It is worth noting that there are four projects in the biotechnology field.
The scale of financing has slowed down, and the growth rate of biotechnology and medicine has been large.
In 2018Q1, there were 132 domestic financial health industry financing incidents, an increase of 8% year-on-year. The total financing amount exceeded US$1.5 billion, an increase of 10% year-on-year. The growth of financing scale slowed down and it has not yet reached the total financing scale of 2016 Q1. However, the scale of financing in the fields of biotechnology and medicine has increased significantly.
Since 2010, the average amount of single financing in the domestic medical and health industry has shown an upward trend, while the domestic financing average has not risen as fast as abroad. In particular, after 2015, the average amount of domestic single financing and the average amount of foreign single financing opened a large gap. The main reason is that the scale of financing in the fields of domestic rehabilitation nursing, science and technology medical care, medical equipment and medical informationization is not as good as that of foreign countries, and the scale of financing for domestic medical consultation and maternal and child health has been greatly reduced.
Financing in the early financing stage decreased, and the financing round moved in the mature direction
Analysis of the financing rounds shows that the overall health care industry in the country has gradually matured, the financing round has moved in the mature direction, and some new projects have emerged.
Biotechnology and medicine have the most gold, and the performance of primary medical and consumer medical fields is bright.
2018Q1 Domestic medical and health industry, biotechnology, medicine, the largest amount of gold, which is the same as the global healthcare industry financing trend. In addition, the performance of primary care, consumer medical, medical information, medical devices and technology and medical fields is outstanding.
In the 2018 domestic medical and health industry, the financing round was dominated by seeds and angels, A round and B round. The proportion of the three was 83%, and the number of A round financing events reached 39% of the total financing events.
In the field of medical informatization, there were 21 financing events. The financing round was dominated by seeds and angels, A round and B round. The proportion of the total financing incidents in the field was as high as 86%.
In the field of biotechnology, there were 19 financing events. The financing rounds were mainly seed and angel rounds, A rounds, B rounds and C rounds. The proportion of the total financing incidents in the field was as high as 84%.
In the pharmaceutical field, there were 19 financing events, and the financing rounds were mainly seed and angel rounds, A rounds and B rounds. The proportion of the total financing incidents in the field was as high as 89%.
The financing of the economically developed regions is the hottest, and the 30% financing incident occurred in Beijing.
The 2018Q1 domestic medical and health industry financing events mainly occurred in the economically developed areas of North, Shanghai, Guangzhou, Jiangsu and Zhejiang. Among them, Beijing financing was the hottest, and the number of financing events accounted for 30% of the total financing of the domestic medical and health industry.
Dinghui, Sequoia, Jingwei are the most active, and the biotechnology, medicine, science and technology medical fields are the most favored.
2018Q1 The most active investment institution in the domestic medical and health industry
2018Q1 There are 209 investment institutions in the domestic medical and health industry. Among them, CDH Investment, Sequoia Capital (China), Jingwei China and other institutions are the most active. The most distributed areas of these investment institutions are biotechnology, medicine, technology, medical care, and consumption. Medical, medical equipment.
2018Q1 domestic medical health industry financing TOP10
2018Q1 Domestic medical and health industry financing TOP10 project financing amount exceeds 50 million US dollars, financing TOP projects are distributed in the fields of biotechnology, medicine, primary care, consumer medical, medical information. It is worth noting that the biotechnology field is favored by capital, and four of the TOP10 accounts for the same trend as the global healthcare industry. In addition, the amount of Hualing Pharmaceutical financing at the top of the list ranked among the top ten in the global healthcare industry.
Hualing Medicine
Established in June 2011, Hualing Medical Technology (Shanghai) Co., Ltd. is a clinical stage drug development company based in China and globally dedicated to the development of breakthrough original innovative drugs. The company's current research and development areas include treatments for type 2 diabetes and treatments for central nervous system disorders. On March 27, 2018, Hualing Pharmaceutical announced the completion of the D and E rounds of financing, raising a total of 117.4 million US dollars. The funds raised are expected to be used to fund the company's completion of two phase III clinical trials of the world's first diabetes Dorzagliatin (HMS5552) in China, as well as commercial pre-marketing preparations. Dorzagliatin (HMS5552) is a new mechanism of the fourth generation of glucokinase active agent, which is effective in treating the functional damage of human blood glucose balance sensor glucokinase, and is expected to solve the root cause of type 2 diabetes.
Yao Mingju
Shanghai Yaoming Junuo Biotechnology Co., Ltd. is a developer of CAR-T cell immunotherapy technology established in China by Juno Therapeutics (NASDAQ:JUNO), the global leader in tumor cell immunotherapy, and WuXi Pharmacon, which was established in China in February 2016. The two companies will combine Juno's world-leading chimeric antigen receptor technology (CAR-T) and T cell receptor (TCR) technology, as well as WuXi Pharma's R&D production platform and the company's extensive local Chinese market experience to jointly build China's leading Cell Therapy Inc. develops innovative cellular immunotherapies for patients with hematological and solid tumors. Its leading CAR-T product, JWCAR029, has successfully declared the IND at the State Food and Drug Administration (CFDA) and entered the clinical trial phase.
At present, Wuming Junuo has established a clinical GMP production facility in line with international standards and quality systems, and has established a leading team with rich experience in biomedicine. On March 8, 2018, Yaoming Junuo announced the completion of the $90 million Series A financing. Li Yiping, co-founder and CEO of Yaoming Juno, said that this round of financing will take the opportunity to continue to promote the clinical trial research of JWCAR029 products, expand research and development pipelines, and establish new industrial production bases.
Virtus Medical Holdings
Virtus Medical Holdings is a private medical service provider in Hong Kong, China. On March 2, 2018, Virtus Medical Holding announced the completion of an $83 million grant from Samena Capital and Millennium Capital.
Biliansheng
Beijing Biliansheng Medical Beauty Clinic Co., Ltd. is the leading enterprise of China's planting chain medical service. The company's business runs through the fields of hairdressing, hair raising, hair transplanting and household products. At present, the direct sales stores cover more than 20 first- and second-tier provincial capital cities across the country, and all of them are directly operated. Biliansheng has the most powerful full-time practitioner team in the industry, including professors, directors and senior members of the World Association of Hair Transplantation.
On January 9, 2018, the investment consortium led by Huagai Capital's Huagai Medical Health Fund completed a strategic holding investment in Biliansheng, a leading pharmaceutical company in China's medical and beauty industry, with a total investment of 500 million yuan. This is currently the largest strategic investment by Huagai Capital in the field of medical beauty.
After the introduction of Huagai Capital, Biliansheng will further strengthen its brand operation, team building and business development, actively seize market share in the hair transplant field and further consolidate its advantages. At the same time, Biliansheng said that with this strategic investment as an opportunity, Bilian Sheng will continue to promote the transformation and upgrading of hair care services, and guide the standardized development of the medical and aesthetic industry in the industry.
Zeng Zhiqiang, the managing partner of Huagai Medical Fund, said that the hairdressing industry, as an important segment of the medical and aesthetic industry, has developed rapidly in the past few years. The hair transplant business has both the demand for medical care and the consumption upgrade of medical beauty, much like the plastic surgery industry 5-10 years ago. The whole industry is at the critical point of the outbreak.
a pulse of sunlight
Yimai Sunshine Imaging Hospital Group was founded in 2014 by a number of Chinese medical imaging industry elites, specializing in medical imaging center investment operations, medical imaging cloud platform technology development, medical imaging talent training, and corresponding three core businesses including independent medical imaging. Center, Medical Imaging Cloud Service, School of Medical Imaging.
At present, Yimai Sunshine has been formed on the basis of a third-party medical imaging center, the medical image cloud platform is a link, and the Medical Imaging Institute is a professionally introduced regional medical imaging medical association model. The network of the First Pulse Sunshine Medical Imaging Center has covered Beijing, Jiangxi, Zhejiang, Shandong, Guangxi, Guangdong, Liaoning, Jilin, Hubei, Hunan, Inner Mongolia and other regions. More than 20 imaging centers have been opened, and the number of daily inspections has exceeded 10,000.
On January 30th, Yimai Sunshine Imaging Hospital Group announced that it had completed the 400 million RMB B round of financing invested by Baidu Capital and Goldman Sachs through the press conference.
Mr. Wang Shihe, founder of Yimai Sunshine, said that in addition to continuing to expand the network of imaging centers, Yimai Sunshine will pay more attention to the construction of talents and technological innovation in the field of medical imaging.
Baidu Capital said that it is very optimistic about the professional team of Sunshine Sunshine, the broad development prospects, and the application of artificial intelligence in the field of medical imaging. In the future, Baidu Capital will help Sunshine Technology upgrade in the fields of artificial intelligence, big data and cloud computing. To improve operational efficiency and the level of intelligent diagnosis.
We're Professional Supplier Extract Powder manufacturers and suppliers in China specialized in providing high-quality products at low price. We warmly welcome you to buy or wholesale bulk Supplier Extract Powder for sale here from our factory. For a free sample, contact us now.
Supplier Extract Powder,Supplier Extract ,Supplier Powder Manufacturer in China
Shaanxi Kang New Pharmaceutical co., Ltd. , https://www.kangnewpharmas.com